Reported Earnings • May 09
First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025) First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025). Reported Earnings • Mar 11
Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024) Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024). 공시 • Mar 05
Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026 Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city Taiwan New Risk • Jan 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). Reported Earnings • Nov 06
Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024) Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024). Reported Earnings • Aug 17
Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024) Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024). Reported Earnings • May 14
First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024) First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024). 공시 • May 06
Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025 Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025 Reported Earnings • Mar 18
Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023) Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023). 공시 • Mar 12
Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025 Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwan 공시 • Mar 04
Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025 Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025 New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change). Reported Earnings • Nov 18
Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023) Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023). 공시 • Nov 01
Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024 Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024 Reported Earnings • Aug 17
Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023) Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023). 공시 • Aug 06
Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024 Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024 New Risk • May 29
New major risk - Revenue and earnings growth Revenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k). 공시 • Mar 27
PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024 PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024. 